Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company and a subsidiary of Fortress Biotech, Inc. The company is dedicated to developing and commercializing innovative cancer immunotherapy products that harness the patient's own immune system to target and eradicate cancer cells. Mustang Bio’s approach involves acquiring the rights to cutting-edge technologies through licensing or ownership, funding their research and development, and then either out-licensing or bringing these technologies to market.
Mustang Bio has established strategic partnerships with notable institutions, including the City of Hope National Medical Center (COH) and the Fred Hutchinson Cancer Research Center. These collaborations focus on developing advanced Chimeric Antigen Receptor (CAR) engineered T cell (CAR T) therapies for various cancers.
Among Mustang’s core projects, their key programs are in Phase 1 clinical trials at COH. The MB-101 program is aimed at treating brain cancer, while MB-102 is being developed as a therapeutic agent for acute myeloid leukemia. Additionally, Mustang Bio is concentrating on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recently, Mustang Bio has reported positive interim data from their multicenter Phase 1/2 clinical trial, showcasing a favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients. For more detailed insights, visit the 65th ASH Annual Meeting and Exposition website.
For further information and ongoing updates about Mustang Bio, you can reach them through the following contacts:
- Jaclyn Jaffe and Nicole McCloskey - Mustang Bio, Inc., (781) 652-4500, ir@mustangbio.com
- Tony Plohoros - Media Relations Contact, 6 Degrees, (908) 591-2839, tplohoros@6degreespr.com
FAQ
What is the current stock price of Mustang Bio (MBIO)?
The current stock price of Mustang Bio (MBIO) is $2.95 as of February 21, 2025.
What is the market cap of Mustang Bio (MBIO)?
The market cap of Mustang Bio (MBIO) is approximately 7.7M.
What is Mustang Bio, Inc.?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products.
What are Mustang Bio's core areas of focus?
Mustang Bio focuses on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Who are Mustang Bio's key partners?
Mustang Bio has partnered with the City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center.
What are Mustang Bio's lead programs?
Mustang Bio's lead programs include MB-101 for brain cancer and MB-102 for acute myeloid leukemia, both in Phase 1 clinical trials.
What recent achievements has Mustang Bio reported?
Mustang Bio recently reported positive interim data from their Phase 1/2 clinical trial indicating a favorable safety and efficacy profile of MB-106 in lymphoma patients.
How does Mustang Bio acquire its technologies?
Mustang Bio acquires technologies through licensing or ownership interests and funds their research and development.
What is CAR T therapy?
CAR T therapy involves engineering a patient's T cells to express a chimeric antigen receptor, enabling them to target and destroy cancer cells.
How can I contact Mustang Bio for more information?
You can contact Mustang Bio via Jaclyn Jaffe and Nicole McCloskey at (781) 652-4500 or email ir@mustangbio.com.
Where can I find more detailed updates on Mustang Bio's clinical trials?
More detailed updates on Mustang Bio's clinical trials can be found on the 65th ASH Annual Meeting and Exposition website.
Who should media inquiries be directed to?
Media inquiries should be directed to Tony Plohoros at 6 Degrees, reachable at (908) 591-2839 or tplohoros@6degreespr.com.